x |
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
o |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
Delaware
|
20-5657551
|
|
(State
or other jurisdiction of incorporation of organization)
|
(I.R.S.
Employer Identification Number)
|
Page
|
|||
PART
I.
|
FINANCIAL
INFORMATION
|
||
Item
1.
|
Financial
Statements (Unaudited)
|
||
Condensed
Consolidated Balance Sheets as of March 31, 2007 and December 31,
2006
|
1
|
||
|
|||
Condensed
Consolidated Statements of Income for the Three-
Month
Periods Ended March 31, 2007 and 2006
|
2
|
||
|
|||
Condensed
Consolidated Statements of Cash Flows for the Three-
Month
Periods Ended March 31, 2007 and 2006
|
3
|
||
|
|||
Notes
to Condensed Consolidated Financial Statements
|
4
|
||
|
|||
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
11
|
|
|
|||
Item
3.
|
Quantitative
and Qualitative Disclosures about Market Risk
|
13
|
|
|
|||
Item
4.
|
Controls
and Procedures
|
13
|
|
|
|||
PART
II.
|
OTHER
INFORMATION
|
|
|
|
|||
Item
1.
|
Legal
Proceedings
|
14
|
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
14
|
|
Item
3.
|
Defaults
upon Senior Securities
|
14
|
|
Item
4.
|
Submission
of Matters to a Vote of Security Holders
|
14
|
|
Item
5.
|
Other
Information
|
14
|
|
Item
6.
|
Exhibits
|
14
|
|
|
|||
SIGNATURES
|
15
|
March
31,
2007
|
December
31,
2006
|
||||||
(Unaudited)
|
(Note
B)
|
||||||
Assets
|
|||||||
Current
assets:
|
|||||||
Cash
and cash equivalents
|
$
|
31,602
|
$
|
24,405
|
|||
Short-term
investments
|
-
|
8,000
|
|||||
Accounts
receivable, net of allowances for doubtful accounts of $150
|
14,303
|
16,724
|
|||||
Inventories
|
208
|
203
|
|||||
Deferred
income taxes
|
4,972
|
4,972
|
|||||
Prepaid
expenses and other current assets
|
1,686
|
1,916
|
|||||
Total
current assets
|
52,771
|
56,220
|
|||||
Equipment,
net of accumulated depreciation of $9,409 and $8,845, respectively
|
4,169
|
4,051
|
|||||
Goodwill
|
2,119
|
2,119
|
|||||
Other
intangible assets, net of accumulated amortization of $1,233 and
$1,205, respectively
|
1,134
|
1,156
|
|||||
Deferred
income taxes
|
1,214
|
885
|
|||||
Other
assets
|
1,064
|
1,229
|
|||||
Total
assets
|
$
|
62,471
|
$
|
65,660
|
|||
Liabilities
and Shareholders’ Equity
|
|||||||
Current
liabilities:
|
|||||||
Accounts
payable
|
$
|
5,212
|
$
|
7,632
|
|||
Accrued
liabilities
|
5,516
|
9,873
|
|||||
Total
current liabilities
|
10,728
|
17,505
|
|||||
Other
liabilities
|
1,252
|
500
|
|||||
Total
liabilities
|
11,980
|
18,005
|
|||||
Shareholders'
equity:
|
|||||||
Common
stock, $.01 par value, 40,000,000 shares authorized, 22,198,698 and
22,086,728 shares issued, respectively
|
222
|
221
|
|||||
Additional
paid-in capital
|
105,248
|
103,122
|
|||||
Accumulated
deficit
|
(55,333
|
)
|
(56,044
|
)
|
|||
Accumulated
other comprehensive loss
|
82
|
79
|
|||||
Nil
coupon perpetual loan notes
|
272
|
277
|
|||||
Total
shareholders' equity
|
50,491
|
47,655
|
|||||
Total
liabilities and shareholders' equity
|
$
|
62,471
|
$
|
65,660
|
Three
Months Ended
March
31
|
|||||||
2007
|
2006
|
||||||
Net
sales
|
$
|
16,262
|
$
|
17,121
|
|||
Costs
and expenses:
|
|||||||
Cost
of sales
|
8,957
|
9,056
|
|||||
Selling,
general and administrative
|
5,906
|
5,424
|
|||||
Research
and development
|
554
|
351
|
|||||
15,417
|
14,831
|
||||||
Operating
income
|
845
|
2,290
|
|||||
Interest
income
|
417
|
150
|
|||||
Other
(expense) income, net
|
(41
|
)
|
(18
|
)
|
|||
Income
before taxes
|
1,221
|
2,422
|
|||||
Income
tax expense
|
(429
|
)
|
(1,072
|
)
|
|||
Net
income
|
$
|
792
|
$
|
1,350
|
|||
Net
income per Common Share:
|
|||||||
Basic
|
$
|
0.04
|
$
|
0.07
|
|||
Diluted
|
$
|
0.03
|
$
|
0.06
|
|||
Weighted-average
number of Common Shares outstanding:
|
|||||||
Basic
|
22,107,000
|
20,613,000
|
|||||
Diluted
|
24,653,000
|
23,708,000
|
Three
Months Ended
March
31
|
|||||||
2007
|
2006
|
||||||
Operating
activities
|
|||||||
Net
cash used in operating activities
|
$
|
(1,342
|
)
|
$
|
(582
|
)
|
|
Investing
activities
|
|||||||
Sales
(purchases) of short-term investments
|
8,000
|
(8,000
|
)
|
||||
Purchases
of equipment and patents
|
(697
|
)
|
(730
|
)
|
|||
Net
cash provided by (used in) investing activities
|
7,303
|
(8,730
|
)
|
||||
Financing
activities
|
|||||||
Proceeds
from exercise of stock options
|
506
|
2,763
|
|||||
Income
tax benefit from exercise of stock options
|
727
|
1,068
|
|||||
Net
cash provided by financing activities
|
1,233
|
3,831
|
|||||
Effect
of exchange rate fluctuations on cash
|
3
|
23
|
|||||
Net
increase (decrease) in cash and cash equivalents
|
7,197
|
(5,458
|
)
|
||||
Cash
and cash equivalents at beginning of period
|
24,405
|
10,375
|
|||||
Cash
and cash equivalents at end of period
|
$
|
31,602
|
$
|
4,917
|
Three
Months Ended March 31
|
|||||||
2007
|
2006
|
||||||
Basic
weighted-average shares
|
22,107,000
|
20,613,000
|
|||||
Conversion
of unsecured loan notes
|
45,000
|
46,000
|
|||||
Unexercised
options and warrants
|
2,501,000
|
3,049,000
|
|||||
Diluted
weighted-average shares
|
24,653,000
|
23,708,000
|
Three
Months Ended March 31
|
|||||||
2007
|
2006
|
||||||
Comprehensive
income:
|
|||||||
Net
income
|
$
|
792
|
$
|
1,350
|
|||
Foreign
currency translation
|
3
|
23
|
|||||
$
|
795
|
$
|
1,373
|
2007
|
2006
|
||||||
Expected
dividend yield
|
0.00
|
%
|
0.00
|
%
|
|||
Risk-free
interest rate
|
4.46
|
%
|
4.70
|
%
|
|||
Expected
volatility
|
56.8
|
%
|
65.6
|
%
|
|||
Expected
life of option
|
5.2
years
|
5.3
years
|
Number
of
Options
|
Weighted-
Average
Exercise
Price
|
Weighted-
Average Remaining Contractual Term
|
Aggregate
Intrinsic Value
|
||||||||||
Outstanding
on January 1, 2007
|
2,414,200
|
$
|
13.02
|
||||||||||
Granted
|
22,000
|
24.66
|
|||||||||||
Exercised
|
(102,250
|
)
|
4.95
|
$
|
2,162
|
||||||||
Expired
or forfeited
|
(44,000
|
)
|
19.10
|
||||||||||
Outstanding
on March 31, 2007
|
2,289,950
|
$
|
13.37
|
8.15
years
|
$
|
30,618
|
|||||||
Exercisable
on March 31, 2007
|
633,700
|
$
|
5.31
|
5.92
years
|
$
|
3,365
|
|||||||
Weighted-average
fair value of
|
|||||||||||||
options
granted during first three months of 2007
|
$
|
13.35
|
Nonvested
Stock Outstanding
|
||||
Outstanding
on January 1, 2007
|
1,702,750
|
|||
Granted
|
22,000
|
|||
Released
|
(24,500
|
)
|
||
Expired
or forfeited
|
(44,000
|
)
|
||
Outstanding
on March 31
|
1,656,250
|
Three
months ended
March
31, 2007
|
Nitrogen
Oxide Reduction
|
Fuel
Treatment Chemical
|
Other
|
Total
|
|||||||||
Net
sales from external customers
|
$
|
8,609
|
$
|
7,653
|
$
|
-
|
$
|
16,262
|
|||||
Cost
of sales
|
5,027
|
3,895
|
35
|
8,957
|
|||||||||
Gross
margin
|
3,582
|
3,758
|
(35
|
)
|
7,305
|
||||||||
Selling,
general and administrative
|
5,906
|
5,906
|
|||||||||||
Research
and development
|
554
|
554
|
|||||||||||
Operating
income (loss)
|
$
|
3,582
|
$
|
3,758
|
$
|
(6,495
|
)
|
$
|
845
|
Three
months ended
March
31, 2006
|
Nitrogen
Oxide Reduction
|
Fuel
Treatment Chemical
|
Other
|
Total
|
|||||||||
Net
sales from external customers
|
$
|
12,365
|
$
|
4,756
|
$
|
-
|
$
|
17,121
|
|||||
Cost
of sales
|
6,888
|
2,118
|
50
|
9,056
|
|||||||||
Gross
margin
|
5,477
|
2,638
|
(50
|
)
|
8,065
|
||||||||
Selling,
general and administrative
|
5,424
|
5,424
|
|||||||||||
Research
and development
|
351
|
351
|
|||||||||||
Operating
income (loss)
|
$
|
5,477
|
$
|
2,638
|
$
|
(5,825
|
)
|
$
|
2,290
|
Three
months ended March 31
|
|||||||
2007
|
2006
|
||||||
Net
sales:
|
|||||||
United
States
|
$
|
14,007
|
$
|
12,906
|
|||
Foreign
|
2,255
|
4,215
|
|||||
$
|
16,262
|
$
|
17,121
|
March
31,
2007
|
December
31,
2006
|
||||||
Assets:
|
|||||||
United
States
|
$
|
58,650
|
$
|
62,190
|
|||
Foreign
|
3,821
|
3,470
|
|||||
$
|
62,471
|
$
|
65,660
|
Date: May 8, 2007 | By: | /s/ John F. Norris Jr. |
John F. Norris Jr. |
||
Director, President and Chief Executive Officer |
Date: May 8, 2007 | By: | /s/ Vincent J. Arnone |
Vincent J. Arnone |
||
Chief
Financial Officer,
Sr.
Vice President and
Treasurer
|